ASP3082 Clinical Trial / KRAS G12D mutation

Posted by tmpeterson16 @tmpeterson16, Mar 21 11:14am

Is anyone currently in the clinical trial study for people with solid tumors with the KRAS G12D mutation? Wondering about side effects they may have experienced and if they have seen favorable results?

Interested in more discussions like this? Go to the Pancreatic Cancer Support Group.

mcharlesfrancis | @mcharlesfrancis | Mar 22 7:20am

Commonly Reported Side Effects
The most frequent treatment-related adverse events (TRAEs) across trials like those for zoldonrasib (RMC-9805), VS-7375, and ASP3082 include:
Gastrointestinal Issues: Nausea, diarrhea, and vomiting are the most common, occurring in 20% to 70% of patients depending on the specific drug.
Skin Reactions: Rashes are frequently observed, particularly with certain targeted inhibitors.
General Fatigue: Feeling unusually tired is a common baseline effect.
Appetite Changes: Decreased appetite and, in some cases, mucosal inflammation or stomatitis (mouth sores).
American Association for Cancer Research (AACR

gamaryanne | @gamaryanne | Mar 22 8:05am

I was in phase 1 of this. Am also in a loop with many that are still on it. Most commonly discussed issues are skin problems. Face, scalp. And fingernails.

Colleen Young, Connect Director | @colleenyoung | Mar 22 3:31pm

@tmpeterson16, in addition to the helpful replied from @gamaryanne and @mcharlesfrancis, I'm also tagging @wpprescott, who was looking into this trial as well.